Mexican health regulator COFEPRIS said on Friday it had approved US pharmaceutical company Pfizer's antiviral oral treatment against COVID-19 for emergency use in adults with light or moderate risk of complications.
Paxlovid, which combines nirmatrelvir and ritonavir in a tablet, will require a prescription, it said in a statement, reports Reuters.
The treatment was nearly 90% effective in preventing hospitalisations and deaths, and data suggested it retains its effectiveness against the omicron variant, Pfizer has said.
Late last year, COFEPRIS had approved a similar treatment by Eli Lilly and Co.
Editor : Shahed Mohammad Ali
Publisher : Abul Kalam Azad
Address: Times Media Bhabon (4th Floor) 387 Tejgaon Industrial Area, Dhaka-1208 l Phone : 55029832-38 l Advertisement : +8801714080378
© 2026 Samakal All Rights Reserved. Developed By Samakal Team.